Tibor Csőszi
About
Tibor Csőszi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Tibor Csőszi has authored 82 papers receiving a total of 10.7k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 17 papers in Surgery. Recurrent topics in Tibor Csőszi's work include Cancer Immunotherapy and Biomarkers (35 papers), Lung Cancer Treatments and Mutations (26 papers) and Lung Cancer Research Studies (18 papers). Tibor Csőszi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (35 papers), Lung Cancer Treatments and Mutations (26 papers) and Lung Cancer Research Studies (18 papers). Tibor Csőszi collaborates with scholars based in United States, Spain and Hungary. Tibor Csőszi's co-authors include Maya Gottfried, Delvys Rodríguez‐Abreu, Sinéad Cuffe, Ali Tafreshi, Rina Hui, Katsuyuki Hotta, Julie R. Brahmer, Nir Peled, Suman Rao and Andrew Robinson and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.
In The Last Decade
Tibor Csőszi
77 papers receiving 10.6k citations
Hit Papers
Peers
Tibor Csőszi
Reshma Rangwala United States
Yue Shentu United States
Maya Gottfried Israel
Katsuyuki Hotta Japan
Suman Rao United States
Andrea Fülöp Hungary
Gregory M. Lubiniecki United States
Mark M. Awad United States
Jamie E. Chaft United States
Hossein Borghaei United States
Citations per year, relative to Tibor Csőszi Tibor Csőszi (= 1×)
peers
Reshma Rangwala
Countries citing papers authored by Tibor Csőszi
Since
Specialization
Citations
This map shows the geographic impact of Tibor Csőszi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tibor Csőszi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tibor Csőszi more than expected).
Fields of papers citing papers by Tibor Csőszi
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Tibor Csőszi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tibor Csőszi. The network helps show where Tibor Csőszi may publish in the future.
Co-authorship network of co-authors of Tibor Csőszi
This figure shows the co-authorship network connecting the top 25 collaborators of Tibor Csőszi. A scholar is included among the top collaborators of Tibor Csőszi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tibor Csőszi. Tibor Csőszi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Casarini, Ignacio, Tibor Csőszi, Mehmet Alı Nahıt Şendur, et al.. (2025). Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial. Annals of Oncology. 36(7). 775–785.
2.
Wakelee, Heather A., Nasser K. Altorki, Caicun Zhou, et al.. (2024). IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(17_suppl). LBA8035–LBA8035.
3.
Aggarwal, Charu, James Stevenson, Dariusz M. Kowalski, et al.. (2024). Abstract CT249: Results from KEYMAKER-U01 substudy 3: a phase 2 umbrella study of pembrolizumab plus investigational agents in patients with non-small-cell lung cancer (NSCLC) previously treated with anti-PD-(L)1 therapy. Cancer Research. 84(7_Supplement). CT249–CT249.
4.
Mehta, Minesh P., Vinai Gondi, Manmeet S. Ahluwalia, et al.. (2024). Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases.. Journal of Clinical Oncology. 42(16_suppl). 2008–2008.
5.
Rodríguez‐Abreu, Delvys, Byoung Chul Cho, Tibor Csőszi, et al.. (2024). Abstract CT253: Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC). Cancer Research. 84(7_Supplement). CT253–CT253.
6.
Powles, Thomas, Tibor Csőszi, Yohann Loriot, et al.. (2024). Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study. Clinical Genitourinary Cancer. 23(1). 102261–102261.
7.
Penkov, Konstantin, Meredith McKean, Mario Mandalà, et al.. (2024). First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study. European Journal of Cancer. 213. 115070–115070.
8.
Ferrarotto, Renata, Ian C. Anderson, Balazs Medgyasszay, et al.. (2021). Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials. Cancer Medicine. 10(17). 5748–5756.
9.
Yang, James Chih‐Hsin, Alexander Luft, Emmanuel de la Mora Jimenez, et al.. (2021). 120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study. Annals of Oncology. 32. S1429–S1430.
10.
Jiménez, M. Martín, Christoph Zielinski, Manuel Ruíz‐Borrego, et al.. (2021). 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study. Annals of Oncology. 32. S457–S458.
11.
Alva, Ajjai, Tibor Csőszi, Mustafa Özgüroğlu, et al.. (2020). LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361. Annals of Oncology. 31. S1155–S1155.
12.
Kim, Hye Ryun, Mark M. Awad, Alejandro Navarro, et al.. (2020). 1782MO Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC. Annals of Oncology. 31. S1033–S1034.
13.
Reck, Martin, Delvys Rodríguez‐Abreu, Rina Hui, et al.. (2019). OA14.01 KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S243–S243.
14.
Reck, Martin, Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2018). 188P Treatment switching–adjusted overall survival (OS) in KEYNOTE-024: First-line pembrolizumab versus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 13(4). S112–S113.
15.
Brahmer, Julie R., Delvys Rodríguez‐Abreu, Andrew Robinson, et al.. (2017). PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024. Journal of Thoracic Oncology. 12(1). S8–S9.
16.
Owonikoko, Taofeek K., Kristiaan Nackaerts, Tibor Csőszi, et al.. (2017). OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC). Journal of Thoracic Oncology. 12(1). S261–S262.
17.
Fayette, Jérôme, Lori J. Wirth, Cristina Oprean, et al.. (2016). Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Frontiers in Oncology. 6. 232–232.
18.
Mądry, Radosław, Ferdinand Haslbauer, Tibor Csőszi, et al.. (2016). Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy. Wiener klinische Wochenschrift. 128(7-8). 238–247.
19.
Belani, Chandra P., Silvia Novello, Joachim von Pawel, et al.. (2015). Randomized, Double-Blind, Placebo-Controlled Trial of Evofosfamide (TH-302) in Combination with Pemetrexed in Advanced Non-Squamous Non-Small Cell Lung Cancer. Annals of Oncology. 26. i29–i29.
20.
Elez, Élena, Ilona Kocáková, Thomas Höhler, et al.. (2014). Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Annals of Oncology. 26(1). 132–140.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Reshma Rangwala Breakdown of academic impact, for papers by Yue Shentu Breakdown of academic impact, for papers by Maya Gottfried Breakdown of academic impact, for papers by Katsuyuki Hotta Breakdown of academic impact, for papers by Suman Rao Breakdown of academic impact, for papers by Andrea Fülöp Breakdown of academic impact, for papers by Gregory M. Lubiniecki Breakdown of academic impact, for papers by Mark M. Awad Breakdown of academic impact, for papers by Jamie E. Chaft Breakdown of academic impact, for papers by Hossein Borghaei